Scar
Conditions
Keywords
Single and bilateral body contouring surgical sites.
Brief summary
The overall goal of this study is to determine the efficacy of tocotrienol (TCT), a natural form of vitamin E, in preventing or reducing scar formation in human skin wounds as well as the basal levels of TCT in normal human skin and adipose tissue.
Detailed description
Scar formation is the physiological and inevitable end point of mammalian wound healing and there is substantial evidence that inflammation is an essential prerequisite for scarring. Although scar tissue restores the normal skin barrier, the new tissue is inferior in structural, aesthetic, and functional respects. The mammalian wound healing response may have originated during the time of high susceptibility to infection. Therefore, we may have developed speed optimized wound healing where a multiple redundant compensating rapid inflammatory response allows the wound to heal quickly without infection. The scar is then the price mammals have to pay for evolutionary survival after being wounded. Tocotrienol may be an effective tool to prevent or reduce normal, hypertrophic, or keloid scarring by mediating the inflammatory response. Tocotrienol is a safe and convenient treatment that could be used by mouth or topically. There has never been a study on the effectiveness of tocotrienol in preventing or reducing scar formation.
Interventions
DIETARY_SUPPLEMENTNatural Vitamin E Tocotrienol supplement (TCT)
Oral Vitamin E Tocotrienol Supplement (TCT)
DEVICENatural Vitamin E Tocotrienol Cream (TCT)
Natural Vitamin E Tocotrienol(TCT)Topical Cream
OTHERPlacebo
Oral Placebo
OTHERPlacebo Cream
Topical Placebo Cream
Sponsors
Chandan K Sen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 18 years of age or older. * Non- smoker * No current medications that alter liver metabolism (e.g., Phenobarbital, HmG co-A inhibitors, etc.) * Non- pregnant or non-breastfeeding * No current use of dietary supplements containing vitamin-E * Not actively abusing drugs or alcohol
Exclusion criteria
* Under 18 years of age * Prisoners * Current smoker * Pregnant or breastfeeding * HIV diagnosis * Viral hepatitis diagnosis * Immunosuppressive therapy * Actively abusing drugs or alcohol * Current use of dietary supplements containing vitamin-E
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To determine the efficacy of TCT in improving the appearance of post-surgical scars following oral supplementation 2.To determine the efficacy of TCT in improving the appearance of post-surgical scars following topical application | 4 weeks prior to surgery and 12 weeks post surgery. |
Countries
United States
Outcome results
None listed